| Title | Authors (identified) | Published In | Identifier(s) | Topic | Published Date | Match? |
|---|
| Tumor-Associated Fibroblasts Promote HER2-Targeted Therapy Resistance through FGFR2 Activation | [1]Patricia Fernández-Nogueira, [2]Mario Mancino, [3]Gemma Fuster, [4]Anna López-Plana, [5]Patricia Jauregui, [6]Vanesa Almendro, [7]Estel Enreig, [8]Silvia Menéndez, [9]Federico Rojo, [10]Aleix Noguera-Castells, [11]Anke Bill, ... [Full author list] | Clinical Cancer Research [missing] | DOI: 10.1158/1078-0432.CCR-19-0353 [ORCID]
PubMed: 31699826 [ORCID]
| | 2019-11-07 | Federico Rojo (Q61766016; 127 items)
|
| Detection of breast cancer stem cell gene mutations in circulating free DNA during the evolution of metastases | [1]Zhe-Bin Liu, [2]Nader E Ezzedine, [3]Agda K Eterovic, [4]Joe E Ensor, [5]Helen J Huang, [6]Joan Albanell, [7]Dong S Choi, [8]Ana Lluch, [9]Yi Liu, [10]Federico Rojo, [11]Helen Wong, [12]Eduardo Martínez-Dueñas, [13]Ángel Guerrero-Zotano, [14]Zhi-Min Shao, [15]Jorge G Darcourt, [16]Gordon B. Mills, [17]Bhuvanesh Dave, [18]Jenny C Chang [Full author list] | Breast Cancer Research and Treatment [missing] | DOI: 10.1007/S10549-019-05374-X [ORCID]
PubMed: 31388936 [ORCID]
| neoplastic stem cells [missing] | 2019-08-06 | Federico Rojo (Q61766016; 127 items)
|
| High Numbers of Circulating CD57+ NK Cells Associate with Resistance to HER2-Specific Therapeutic Antibodies in HER2+ Primary Breast Cancer | [1]Aura Muntasell, [2]Sònia Servitja, [3]Mariona Cabo, [4]Begoña Bermejo, [5]Sandra Pérez-Buira, [6]Federico Rojo, [7]Marcel Costa-Garcia, [8]Oriol Arpí, [9]Manuela Moraru, [10]Laia Serrano, ... [Full author list] | Cancer Immunology Research [missing] | DOI: 10.1158/2326-6066.CIR-18-0896 [ORCID]
PubMed: 31189644 [ORCID]
| | 2019-06-12 | Federico Rojo (Q61766016; 127 items)
|
| Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Kα Inhibitor TAK-117 in Preclinical Bladder Cancer Models | [1]Anna Hernández-Prat, [2]Alejo Rodriguez-Vida, [3]Nuria Juanpere-Rodero, [4]Oriol Arpi, [5]Silvia Menéndez, [6]Luis Soria-Jiménez, [7]Alejandro Martínez, [8]Natalia Iarchouk, [9]Federico Rojo, [10]Joan Albanell, [11]Rachael Brake, [12]Ana Rovira, [13]Joaquim Bellmunt [Full author list] | Molecular Cancer Research [missing] | DOI: 10.1158/1541-7786.MCR-18-0923 [ORCID]
PubMed: 31160383 [ORCID]
| paclitaxel [missing] | 2019-06-03 | Federico Rojo (Q61766016; 127 items)
|
| Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone | [1]Ivana Sestak, [2]Miguel Martín, [3]Peter Dubsky, [4]Ralf Kronenwett, [5]Federico Rojo, [6]Jack Cuzick, [7]Martin Filipits, [8]Amparo Ruiz, [9]William Gradishar, [10]Hatem Soliman, [11]Lee Schwartzberg, [12]Richard Buus, [13]Dominik Hlauschek, [14]Alvaro Rodríguez-Lescure, [15]Michael Gnant [Full author list] | Breast Cancer Research and Treatment [missing] | DOI: 10.1007/S10549-019-05226-8 [ORCID]
PubMed: 31041683 [ORCID]
| chemotherapy [missing] | 2019-04-30 | Federico Rojo (Q61766016; 127 items)
|
| The miRNA-449 family mediates doxorubicin resistance in triple-negative breast cancer by regulating cell cycle factors | [1]Eduardo Tormo, [2]Sandra Ballester, [3]Anna Adam-Artigues, [4]Octavio Burgués, [5]Elisa Alonso, [6]Begoña Bermejo, [7]Silvia Menéndez, [8]Sandra Zazo, [9]Juan Madoz-Gúrpide, [10]Ana Rovira, [11]Joan Albanell, [12]Federico Rojo, [13]Ana Lluch, [14]Pilar Eroles [Full author list] | Scientific Reports [missing] | DOI: 10.1038/S41598-019-41472-Y [ORCID]
PubMed: 30926829 [ORCID]
| doxorubicin [missing]; triple-negative breast cancer [missing] | 2019-03-29 | Federico Rojo (Q61766016; 127 items)
|
| Publisher Correction: MSK1 regulates luminal cell differentiation and metastatic dormancy in ER+ breast cancer | [1]Sylwia Gawrzak, [2]Lorenzo Rinaldi, [3]Sara Gregorio, [4]Enrique J Arenas, [5]Fernando Salvador, [6]Jelena Urosevic, [7]Cristina Figueras-Puig, [8]Federico Rojo, [9]Ivan Del Barco Barrantes, [10]Juan Miguel Cejalvo, ... [Full author list] | Nature Cell Biology [missing] | DOI: 10.1038/S41556-018-0052-0 [ORCID]
PubMed: 29674681 [ORCID]
| cell differentiation [missing] | 2018-08-01 | Federico Rojo (Q61766016; 127 items)
|
| A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. GEICAM/2010-04 study | [1]Alberto Ocana, [2]Marta Gil-Martin, [3]Miguel Martín, [4]Federico Rojo, [5]Silvia Antolín, [6]Ángel Guerrero, [7]José Manuel Trigo, [8]Montse Muñoz, [9]Atanasio Pandiella, [10]Núria Gonzalo Diego, [11]Susana Bezares, [12]Rosalía Caballero, [13]Eva Carrasco, [14]Ander Urruticoechea [Full author list] | Oncotarget [missing] | DOI: 10.18632/ONCOTARGET.17113 [ORCID]
PubMed: 29069857 [ORCID]
| trastuzumab [missing]; dasatinib [missing]; paclitaxel [missing]; dasatinib monohydrate [missing]; overexpression [missing] | 2017-04-14 | Federico Rojo (Q61766016; 127 items)
|
| First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors. | [1]Maria Martinez-Garcia, [2]Udai Banerji, [3]Joan Albanell, [4]Rastilav Bahleda, [5]Saoirse Dolly, [6]Françoise Kraeber-Bodéré, [7]Federico Rojo, [8]Emilie Routier, [9]Ernesto Guarin, [10]Zhi-Xin Xu, [11]Ruediger Rueger, [12]Jean J L Tessier, [13]Eliezer Shochat, [14]Steve Blotner, [15]Valerie Meresse Naegelen, [16]Jean-Charles Soria, [16-Q33120580]Jean-Charles Soria [Full author list] | Clinical Cancer Research [missing] | DOI: 10.1158/1078-0432.CCR-12-0742 [ORCID]
PubMed: 22761467 [ORCID]
| patient [missing]; pharmacokinetics [missing]; pharmacodynamics [missing]; avutometinib [missing] | 2012-07-03 | Federico Rojo (Q61766016; 127 items)
|
| Nuclear NF-κB/p65 expression and response to neoadjuvant chemotherapy in breast cancer. | [1]Robin L Jones, [2]Federico Rojo, [3]Roger A'Hern, [4]Nadia Villena, [5]Janine Salter, [6]Josep Maria Corominas, [7]Sonia Servitja, [8]Ian E Smith, [9]Ana Rovira, [10]Jorge Reis-Filho, [11]Mitchell Dowsett, [12]Joan Albanell [Full author list] | Journal of Clinical Pathology [missing] | DOI: 10.1136/JCP.2010.082966 [ORCID]
PubMed: 21148141 [ORCID]
| NF-κB [missing]; chemotherapy [missing] | 2010-12-08 | Federico Rojo (Q61766016; 127 items)
|
| Cytogenetic characterization of NCI-H69 and NCI-H69AR small cell lung cancer cell lines by spectral karyotyping | [1]Marta Salido, [2]Edurne Arriola, [3]Alma Carracedo, [4]Israel Cañadas, [5]Ana Rovira, [6]Blanca Espinet, [7]Federico Rojo, [8]Montse Arumi, [9]Sergi Serrano, [10]Joan Albanell, [11]Francesc Sole [Full author list] | Cancer Genetics and Cytogenetics [missing] | DOI: 10.1016/J.CANCERGENCYTO.2009.01.016 [ORCID]
PubMed: 19446745 [ORCID]
| karyotype [missing] | 2009-06-01 | Federico Rojo (Q61766016; 127 items)
|
| FISH and immunohistochemical status of the hepatocyte growth factor receptor (c-Met) in 184 invasive breast tumors | [1]Alma Carracedo, [2]Kristof Egervari, [3]Marta Salido, [4]Federico Rojo, [5]Josep M Corominas, [6]Montserrat Arumi, [7]Cristina Corzo, [8]Ignacio Tusquets, [9]Blanca Espinet, [10]Ana Rovira, [11]Joan Albanell, [12]Zoltan Szollosi, [13]Sergi Serrano, [14]Francesc Solé [Full author list] | Breast Cancer Research [missing] | DOI: 10.1186/BCR2239 [ORCID]
PubMed: 19439036 [ORCID]
| immunohistochemistry [missing] | 2009-04-21 | Federico Rojo (Q61766016; 127 items)
|
| Targeted therapies in breast cancer | [1]Federico Rojo, [2]Joan Albanell, [3]Ana Rovira, [4]Josep Maria Corominas, [5]Felix Manzarbeitia [Full author list] | Seminars in Diagnostic Pathology [missing] | DOI: 10.1053/J.SEMDP.2008.08.001 [ORCID]
PubMed: 19013891 [ORCID]
| | 2008-11-01 | Federico Rojo (Q61766016; 127 items)
|
| Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors | [1]Josep Tabernero Caturla, [2]Federico Rojo, [3]Emiliano Calvo, [4]Howard Burris, [5]Ian Judson, [6]Katharine Hazell, [7]Erika Martinelli, [8]Santiago Ramon y Cajal, [9]Suzanne Jones, [10]Laura Vidal, [11]Nicholas Shand, [12]Teresa Macarulla, [13]Francisco J Ramos, [14]Sasa Dimitrijevic, [15]Ulrike Zoellner, [16]Pui Tang, [17]Michael Stumm, [18]Heidi A Lane, [19]David Lebwohl, [20]José Baselga [Full author list] | Journal of Clinical Oncology [missing] | DOI: 10.1200/JCO.2007.14.5482 [ORCID]
PubMed: 18332469 [ORCID]
| sirolimus [missing]; patient [missing]; pharmacodynamics [missing] | 2008-03-10 | Federico Rojo (Q61766016; 127 items)
|
| Phase I pharmacokinetic/pharmacodynamic study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in first-line treatment of patients | [1]Gunnar Folprecht, [2]Josep Tabernero Caturla, [3]Claus-Henning Köhne, [4]Charles Zacharchuk, [5]Luis Paz-Ares, [6]Federico Rojo, [7]Susan Quinn, [8]Esther Casado, [9]Ramon Salazar, [10]Richat Abbas, [11]Chantal Lejeune, [12]Irene Marimón, [13]Jordi Andreu, [14]Ulrike Ubbelohde, [15]Hernan Cortes-Funes, [16]Josep Baselga [Full author list] | Clinical Cancer Research [missing] | DOI: 10.1158/1078-0432.CCR-07-1053 [ORCID]
PubMed: 18172273 [ORCID]
| fluorouracil [missing]; pharmacokinetics [missing]; irinotecan [missing]; pharmacodynamics [missing] | 2008-01-01 | Federico Rojo (Q61766016; 127 items)
|
| 4E-binding protein 1: a key molecular "funnel factor" in human cancer with clinical implications | [1]Gemma Armengol, [2]Federico Rojo, [3]Josep Castellvi, [4]Carmela Iglesias, [5]Miriam Cuatrecasas, [6]Berta Pons, [7]José Baselga, [8]Santiago Ramon y Cajal [Full author list] | Cancer Research [missing] | DOI: 10.1158/0008-5472.CAN-07-0881 [ORCID]
PubMed: 17699757 [ORCID]
| | 2007-08-01 | Federico Rojo (Q61766016; 127 items)
|
| Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer | [1]Maurizio Scaltriti, [2]Federico Rojo, [3]Alberto Ocana, [4]Judit Anido, [5]Marta Guzman, [6]Javier Cortes, [7]Serena Di Cosimo, [8]Xavier Matias-Guiu Guia, [9]Santiago Ramon y Cajal, [10]Joaquin Arribas, [11]José Baselga [Full author list] | Journal of the National Cancer Institute [missing] | DOI: 10.1093/JNCI/DJK134 [ORCID]
PubMed: 17440164 [ORCID]
| | 2007-04-01 | Federico Rojo (Q61766016; 127 items)
|
| Apocrine carcinoma of the anogenital region. A case report including immunohistochemical and molecular study, discussion of differential diagnosis and a review of the literature | [1]Javier de la Torre Fernández de Vega, [2]Pere Huguet, [3]Alfredo Santana, [4]Carmen Ruiz de Miguel, [5]Federico Rojo, [6]Santiago Ramon y Cajal, [7]Eduardo Salido [Full author list] | International Journal of Colorectal Disease [missing] | DOI: 10.1007/S00384-006-0255-X [ORCID]
PubMed: 17333218 [ORCID]
| immunohistochemistry [missing] | 2007-03-01 | Federico Rojo (Q61766016; 127 items)
|
| High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. | [1]Alejandra Bruna, [2]Rachel S Darken, [3]Federico Rojo, [4]Alberto Ocaña, [5]Silvia Peñuelas, [6]Alexandra Arias, [7]Raquel Paris, [8]Avelina Tortosa, [9]Jaume Mora, [10]Josep Baselga, [11]Joan Seoane [Full author list] | Cancer Cell [missing] | DOI: 10.1016/J.CCR.2006.11.023 [ORCID]
PubMed: 17292826 [ORCID]
| patient [missing] | 2007-02-01 | |
| 4E-binding protein 1, a cell signaling hallmark in breast cancer that correlates with pathologic grade and prognosis | [1]Federico Rojo, [2]Laura Najera, [3]José Lirola, [4]José Jiménez, [5]Marta Guzmán, [6]M Dolors Sabadell, [7]Josep Baselga, [8]Santiago Ramon y Cajal [Full author list] | Clinical Cancer Research [missing] | DOI: 10.1158/1078-0432.CCR-06-1560 [ORCID]
PubMed: 17200342 [ORCID]
| | 2007-01-01 | Federico Rojo (Q61766016; 127 items)
|
| Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer | [1]Josep Castellvi, [2]Angel Garcia, [3]Federico Rojo, [4]Carmen Ruiz-Marcellan, [5]Antonio Gil, [6]Jose Baselga, [7]Santiago Ramon y Cajal [Full author list] | Cancer [missing] | DOI: 10.1002/CNCR.22195 [ORCID]
PubMed: 16983702 [ORCID]
| ovarian cancer [missing] | 2006-10-01 | Federico Rojo (Q61766016; 127 items)
|
| Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma | [1]Federico Rojo, [2]Josep Tabernero Caturla, [3]Joan Albanell, [4]Eric Van Cutsem, [5]Atsushi Ohtsu, [6]Toshihiko Doi, [7]Wasaburo Koizumi, [8]Kuniaki Shirao, [9]Hiroya Takiuchi, [10]Santiago Ramon y Cajal, [11]José Baselga [Full author list] | Journal of Clinical Oncology [missing] | DOI: 10.1200/JCO.2005.04.2424 [ORCID]
PubMed: 16963731 [ORCID]
| patient [missing]; pharmacodynamics [missing] | 2006-09-01 | Federico Rojo (Q61766016; 127 items)
|
| Reduction of cytosolic p27(Kip1) inhibits cancer cell motility, survival, and tumorigenicity | [1]Frederick Y Wu, [2]Shizhen Emily Wang, [3]Melinda E Sanders, [4]Incheol Shin, [5]Federico Rojo, [6]Josep Baselga, [7]Carlos L Arteaga [Full author list] | Cancer Research [missing] | DOI: 10.1158/0008-5472.CAN-05-3304 [ORCID]
PubMed: 16489017 [ORCID]
| | 2006-02-01 | |
| p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer | [1]Rosana Sáez, [2]Miguel A Molina, [3]Elizabeth E Ramsey, [4]Federico Rojo, [5]Edward J Keenan, [6]Joan Albanell, [7]Ana Lluch, [8]Javier García-Conde, [9]José Baselga, [10]Gail M Clinton [Full author list] | Clinical Cancer Research [missing] | DOI: 10.1158/1078-0432.CCR-05-1807 [ORCID]
PubMed: 16428482 [ORCID]
| | 2006-01-01 | Federico Rojo (Q61766016; 127 items)
|
| Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer | [1]José Baselga, [2]Joan Albanell, [3]Amparo Ruiz, [4]Ana Lluch, [5]Pere Gascón, [6]Vicente Guillém, [7]Sonia González, [8]Silvia Sauleda, [9]Irene Marimón, [10]Josep Tabernero Caturla, [11]Maria T Koehler, [12]Federico Rojo [Full author list] | Journal of Clinical Oncology [missing] | DOI: 10.1200/JCO.2005.08.326 [ORCID]
PubMed: 15939921 [ORCID]
| patient [missing]; pharmacodynamics [missing] | 2005-06-06 | Federico Rojo (Q61766016; 127 items)
|
| Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting | [1]Pablo Matar, [2]Federico Rojo, [3]Raúl Cassia, [4]Gema Moreno-Bueno, [5]Serena Di Cosimo, [6]Josep Tabernero Caturla, [7]Marta Guzmán, [8]Sonia Rodriguez, [9]Joaquin Arribas, [10]José Palacios, [11]José Baselga [Full author list] | Clinical Cancer Research [missing] | DOI: 10.1158/1078-0432.CCR-04-0870 [ORCID]
PubMed: 15475436 [ORCID]
| antibody [missing]; cetuximab [missing] | 2004-10-01 | Federico Rojo (Q61766016; 127 items)
|
| Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor | [1]Udo Vanhoefer, [2]Mitra Tewes, [3]Federico Rojo, [4]Olaf Dirsch, [5]Norbert Schleucher, [6]Oliver Rosen, [7]Joachim Tillner, [8]Andreas Kovar, [9]Ada H Braun, [10]Tanja Trarbach, [11]Siegfried Seeber, [12]Andreas Harstrick, [13]José Baselga [Full author list] | Journal of Clinical Oncology [missing] | DOI: 10.1200/JCO.2004.05.114 [ORCID]
PubMed: 14701780 [ORCID]
| antibody [missing]; patient [missing]; monoclonal antibody [missing] | 2004-01-01 | Federico Rojo (Q61766016; 127 items)
|
| ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells | [1]Judit Anido, [2]Pablo Matar, [3]Joan Albanell, [4]Marta Guzmán, [5]Federico Rojo, [6]Joaquin Arribas, [7]Steve Averbuch, [8]Josep Baselga [Full author list] | Clinical Cancer Research [missing] | PubMed: 12684395 [ORCID]
| overexpression [missing] | 2003-04-01 | |
| PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization | [1]Incheol Shin, [2]F Michael Yakes, [3]Federico Rojo, [4]Nah-Young Shin, [5]Andrei V Bakin, [6]Josep Baselga, [7]Carlos L Arteaga [Full author list] | Nature Medicine [missing] | DOI: 10.1038/NM759 [ORCID]
PubMed: 12244301 [ORCID]
| phosphorylation [missing] | 2002-09-16 | |
| Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial | [1]Roy S. Herbst, [2]Anne-Marie Maddox, [3]Mace L Rothenberg, [4]Eric J Small, [5]Eric H Rubin, [6]Josep Baselga, [7]Federico Rojo, [8]Waun Ki Hong, [9]Helen Swaisland, [10]Steven D Averbuch, [11]Judith Ochs, [12]Patricia Mucci LoRusso [Full author list] | Journal of Clinical Oncology [missing] | DOI: 10.1200/JCO.2002.03.038 [ORCID]
PubMed: 12228201 [ORCID]
| lung cancer [missing]; phase I clinical trial [missing] | 2002-09-01 | |
| NH(2)-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer | [1]Miguel A Molina, [2]Rosana Sáez, [3]Elizabeth E Ramsey, [4]María-José Garcia-Barchino, [5]Federico Rojo, [6]Adam J Evans, [7]Joan Albanell, [8]Edward J Keenan, [9]Ana Lluch, [10]Javier García-Conde, [11]José Baselga, [12]Gail M Clinton [Full author list] | Clinical Cancer Research [missing] | PubMed: 11839648 [ORCID]
| breast cancer [missing] | 2002-02-01 | Federico Rojo (Q61766016; 127 items)
|
| Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition | [1]Joan Albanell, [2]Federico Rojo, [3]Steve Averbuch, [4]Andrea Feyereislova, [5]Jose Manuel Mascaro, [6]Roy S. Herbst, [7]Patricia LoRusso, [8]Danny Rischin, [9]Silvia Sauleda, [10]Julia Gee, [11]Robert I Nicholson, [12]Josep Baselga [Full author list] | Journal of Clinical Oncology [missing] | DOI: 10.1200/JCO.20.1.110 [ORCID]
PubMed: 11773160 [ORCID]
| pharmacodynamics [missing] | 2002-01-01 | |